Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer’s cut-price version of Avastin wins EU panel greenlight

A panel of European Medicines Agency recommended approval for Pfizer Inc.’s Zirabev, a cheaper version to Roche Holding AG’s leading cancer drug Avastin.

Read More »

J&J shares nosedive on report company knew of asbestos in baby powder

Shares of Johnson & Johnson tumbled 12 percent after Reuters reported that the pharma major knew for decades that cancer-causing asbestos lurked in the company’s Baby Powder.

Read More »

Inflammatory bowel disease tied to heart attack risk

People with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may be up to 12 times more likely to have a heart attack, a U.S. study suggests.

Read More »

Senate Democrats introduce bill to allow government to block drug price rises

Four Democratic U.S. senators introduced a bill that would allow the government to block drug price increases that are unjustified.

Read More »

Google launches Thai AI project to screen for diabetic eye disease

Google said on Thursday the company had launched an artificial intelligence program in Thailand to screen for a diabetic eye disease that causes permanent blindness.

Read More »

Mylan says Sanofi loses Lantus insulin patent claims

U.S. generics drugmaker Mylan said the United States Patent and Trademark Office rejected Sanofi’s infringement claims relating to insulin drug Lantus.

Read More »

Radical surgery for some prostate cancers adds three years to life

In men with localized prostate cancer discovered because they had symptoms or noticed during a work-up for another medical problem, radical prostate surgery leads to an average of three extra years of life compared to a “watchful waiting” approach, researchers say.

Read More »

J&J says its psoriasis drug superior to Novartis’ in study

Johnson & Johnson said the company’s drug Tremfya was more effective than Novartis AG’s rival medicine Cosentyx, and met the main goal of a late-stage study in adults with moderate-to-severe plaque psoriasis.

Read More »

FDA declines to approve Mallinckrodt’s abuse-deterrent opioid painkiller

The U.S. Food and Drug Administration declined to approve an abuse-deterrent version of Mallinckrodt Plc’s opioid painkiller Roxicodone, saying some parts of the company’s application need further evaluation.

Read More »

Lilly partners with AC Immune for Alzheimer’s treatment

U.S. drugmaker Eli Lilly and Co. and AC Immune SA agreed to jointly develop the Swiss biotech’s potential treatment for Alzheimer’s disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom